Nurix Therapeutics Inc logo

NRIX

Nurix Therapeutics Inc

$10.2

Earnings Summary

Revenue
$15.16Mn
Net Profits
$-41.96Mn
Net Profit Margins
-276.77%

Highlights

Revenue:

Nurix Therapeutics Inc’s revenue jumped 123.49% since last year same period to $15.16Mn in the Q4 2023. On a quarterly growth basis, Nurix Therapeutics Inc has generated -17.91% fall in its revenue since last 3-months.

Net Profits:

Nurix Therapeutics Inc’s net profit fell -0.6% since last year same period to $-41.96Mn in the Q4 2023. On a quarterly growth basis, Nurix Therapeutics Inc has generated -13.45% fall in its net profits since last 3-months.

Net Profit Margins:

Nurix Therapeutics Inc’s net profit margin jumped 54.99% since last year same period to -276.77% in the Q4 2023. On a quarterly growth basis, Nurix Therapeutics Inc has generated -38.21% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Nurix Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.82
EPS Estimate Current Year
-0.82

Highlights

EPS Estimate Current Quarter:

Nurix Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.82 - a -43.86% fall from last quarter’s estimates.

EPS Estimate Current Year:

Nurix Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.82.

Key Ratios

Key ratios of the Nurix Therapeutics Inc post its Q4 2023 earnings

Earning Per Share (EPS)
-0.77
Return on Assets (ROA)
-0.25
Return on Equity (ROE)
-0.57

Highlights

Earning Per Share (EPS):

Nurix Therapeutics Inc’s earning per share (EPS) jumped 11.49% since last year same period to -0.77 in the Q4 2023. This indicates that the Nurix Therapeutics Inc has generated 11.49% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Nurix Therapeutics Inc’s return on assets (ROA) stands at -0.25.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Nurix Therapeutics Inc’s return on equity (ROE) stands at -0.57.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2023-10-12
-0.76
-0.68
10.53%
2023-04-13
-0.87
-0.75
13.79%
2023-07-13
-0.56
-0.45
19.64%